Edgewise Therapeutics, Inc. (EWTX)

Market Cap	3.03B
Revenue (ttm)	n/a
Net Income (ttm)	-124.29M
Shares Out	94.69M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	332,369
Open	31.44
Previous Close	31.51
Day's Range	31.06 - 32.08
52-Week Range	5.93 - 38.12
Beta	0.15
Analysts	Strong Buy
Price Target	40.40 (+26.45%)
Earnings Date	Nov 7, 2024

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX
• Website: https://www.edgewisetx.com

Analyst Forecast

According to 5 analysts, the average rating for EWTX stock is "Strong Buy." The 12-month stock price forecast is $40.4, which is an increase of 26.45% from the latest price.

Price Target

$40.4

(26.45% upside)

Analyst Consensus: Strong Buy